The LP-BM5 murine retrovirus-induced immunodeficiency model was used to evaluate the efficacy and toxicity of long-term 2',3'-dideoxycytidine (DOC) therapy. A mean plasma drug concentrejlon of 0.2 ± 0.02 jiM of DDC for 3 months was founeP'to reduce splenomegaly, Iymphoadenopathy and hypergamma-. globulinemia in infected mice. However, DDC also reduced spleen weight in control mice and spleen haemopoiesis in both infected and uninfected animals. In the bone marrow the most prominent feature of DOC treatment was a marked reduction of megakariocytes, while in the liver an hepatocellular vacuolation was evident in uninfected animals. DDC reduced, butdld not prevent, LP-BM5 integration in lymph node DNA and Pr 60 g ag expression in spleen lymphocytes and bone marrow cells. Furthermore, DDC reduced the mitochondrial DNA content and restored the mitogen proliferation of T cells but not that of B cells in infected mice. Thus, DDC appears to be of some, but limited, efficacy in murine AIDS, with a toxicity profile involving more cell types than previously thought. Received
Introduction 2',3'-Dideoxycytidine (DOC, zalcitabine) is a nucleoside analogue of deoxycytidine which, when intracellularly phosphorylated to the corresponding 5'-triphosphate derivative (DDCTP), inhibits HIV-1 replication. DOC is currently in use in combination with zidovudine (AZT) or in patients who have received previous zidovudine therapy. In both cases, DOC improves the CD4 lymphocyte count and p24 antigen level (Yarchoan et al., 1988; Merigan et al., 1989; Fischl et al., 1993; Hirsch and D'Aquila, 1993) . The major toxicity associated with DOC is a reversible peripheral neuropathy (Yarchoan et al., 1988; Merigan et al., 1989; Berger et al., 1993) which develops after a few weeks of treatment. Several in vitro studies have shown that DOC can inhibit cell growth at high concentrations (> 5 jiM), probably because it is incorporated into cellular DNA (Starnes and Cheng, 1987; Ullman et al., 1988; Brandi et al., 1991) . However, at therapeutic concentrations (0.1-0.2jiM) DOC causes a delayed cytotoxicity and a selective loss of mitochondrial DNA (Chen and Cheng, 1989 ), suggesting that inhibition of mitochondrial DNA replication is the primary step in DOC-induced peripheral neuropathy (Keilbaugh et al., 1991) . Unfortunately, in vivo toxicity data are very limited and fragmentary. DOC has shown developmental toxicity in mice (Lindstrom et al., 1990) , and neuropathy in rabbits Feldman et al., 1992) . At tolerable doses, DOC causes thrombocytopenia, megakaryocyte hypoplasia and hepatocellular vacuolation in cats (polas et al., 1990) . To understand better the mechanism(s) of in vivo DOC toxicity we have used the LP-BM5 murine retrovirus-induced immunodeficiency model. Although HIV and LP-BM5 are retroviruses of different classes and their infectivities involve distinct virus-host interactions, the induced syndromes share many features including immunodeficiency, enhanced susceptibility to infections and latestage lymphomas (Morse et aI., 1992) . DOC was found to reduce the disease status of infected mice but, using a combination of techniques, several cell types were shown to present clear signs of toxicity.
Results
Infection of C57BU6 mice with the LP-BM5 retrovirus complex causes a disease with a pathology that resembles human AIDS in many aspects (Jolicoeur, 1991; Morse et al., 1992) . We have treated infected and control mice (10 animals in each group) for 3 months with oral DOC. The dose selected provided a mean plasma concentration of 0.2 ± 0.02 jiM, both in normal and in infected mice, which is similar to the DOC concentration commonly found in patients receiving this drug (Broder, 1990) . Ten infected untreated animals and 10 uninfected, untreated mice served as controls. All mice were sacrified after 3 months of treatment. 
Disease progression
Development of splenomegaly and Iymphoadenopathy in infected mice was found to be weakly dependent upon the virus pool used. For the experiments reported in this paper a single pool of LP-BM5 isolated from SC-1 infected cells was used. Three months after virus inoculation (see 'Materials and Experimental Procedures' for details), all mice developed splenomegaly and Iymphoadenopathy and DOC treatment of infected mice reduced spleen weight and lymph node weight as already documented . DOC administered to uninfected animals reduced spleen weight from 92 ± 8 mg to 56 ± 1 mg and lymph node weight from 75 ± 26 mg to 50 ± 7 mg. (All values are mean ± SO of 10 animals.) The lymph nodes examined include the mediastinal, brachial, lumbar, mesenteric and inguinal nodes.
The peak plasma IgG and IgM concentrations occurred at week 9 from infection, and DOC reduced the IgG concentration from 540 mg (100 ml)-1 to 330 mg (100 mlf1 while the IgM concentration was almost unaffected [60 mg (100 mlf1] . No effect of DOC was noted on the plasma IgG and IgM concentrations in uninfected animals [90 and 10 mg (100 ml)-1, respectively].
Histopathological examination
Samples of spleen, bone marrow and liver from three animals in each group were fixed, sectioned and stained. As shown in Fig. 1 , prominent features in the livers of infected mice are marked lymphoid infiltrates which are significantly reduced by DOC administration. Furthermore, DOC causes hepatocellular vacuolation in the controls but not in infected mice. In the spleen, erythropoiesis appears to be reduced by DOC both in controls and in infected mice. In the bone marrow DOC causes the almost complete disappearance of megakaryocytes. DOC seems partially to restore the bone marrow cytopenias of murine AIDS (Magnani et al., 1993) , with the exception of megakaryocytes. Immunostaining was with a goat anti-p30 antibody that recognizes the Pr60 g ag protein expressed on the surface of infected cells. Detection was with a gOld-conjugated rabbit anti-goat IgG antibody and by silver enhancing (magnification x400).
Virus expression
The expression of virus protein was studied by immunocytochemistry using an anti-p30 antibody. This antibody recognizes the Pr 60 g a g product of the virus (Aziz et al., 1989; Chattopadhyay et al., 1991) . We have previously Shown (Rossi et al., 1993 ) that DOC does not significantly reduce the expression of viral protein on the surface of peritoneal macrophages and lymph node lymphocytes. Fig.2 shows that instead DOC reduces Pr60 g ag expression in the bone marrow cells and also reduces it slightly ( Fig. 3 ) in spleen cells. However, the antibody used does not discriminate between Pr60 ga g products of ecotropic and defective viruses. These results should therefore be interpreted with caution.
Virus integration
The inhibition of LP-BM5 integration into lymph node lymphocyte DNA was investigated with a recently developed PCR method (see 'Materials and Experimental Procedures'). As shown in Fig. 4 , DOC was found to reduce LP-BM5 integration. Laser scan densitometry of the autoradiographs gave a mean percentage reduction of 83.2 ± 3% (mean ± SO, n = 10).
Mitochondrial DNA
Since one possible mechanism of DOC toxicity appears to be the inhibition of mitochondrial DNA replication (Chen and Cheng, 1989) , we examined the effect of DOC on the content of lymph node mitochondrial DNA in the treated mice. As shown in Fig. 5 , DOC causes a 22 ± 2% reduction of mitochondrial DNA in the infected animals and a 25 ± 3% reduction in the controls (uninfected, DDCtreated mice).
Lymphocyte responses to mitogens
Spleen lymphocytes were prepared from the four groups of animals 3 months after the beginning of the experiment. As shown in Fig. 6 , Band T cells from infected mice show a marked reduction in their ability to respond to mitogens. DOC almost completely restores the proliferative response of T cells but has no effect on the B cells. A 25% reduction of T-cell response was found in control animals treated with DOC.
Other determinations
DOC was previously found (Rossi et al., 1993) to be unable to restore the normal percentage of Thy 1.2 positive cells present in the lymph nodes of infected mice. No effect of DOC on the percentage of Thy 1.2 positive cells was found in control mice during the experiments reported here (data not shown).
In vitro studies on the mechanism of DOC toxicity have shown an increased production of lactic acid concomitant with the decrease of mitochondrial DNA (Chen and Cheng, 1989) . In vivo, DOC does not cause an increase of blood lactate in infected mice after three months from infection (Rossi et al., 1993) . Measurements of blood lactate performed on control animals treated with DOC for the same period of time indicated an unmodified lactate concentration (7.9 ± 1.5 .umol rnl" blood; normal controls 7.2 ± 2 .umol ml-1 blood).
Several blood parameters, including serum enzymes, were investigated. A modification of one of these that can probably be attributed to DOC was a reduction of the mean cell haemoglobin, with values of 16.1 ± 2 and 18.0 ± 2 pg cell-1 in the controls and infected animals receiving DOC, while values of 21 ± 3 and 19.5 ±3 pg cell-1 , respectively, were found in controls and infected mice not treated with DOC.
Discussion
DOC therapy in HlV-infected patients has been shown to improve the CD4 lymphocyte count and the p24 antigen level (Yarchoan et al., 1988; Merigan et al., 1989) . In advanced HlV disease, DOC has been reported to be of more benefit than zidovudine (AZT) (Fischl et al., 1993) , although no differences in survival or clinical end-point were found. The most frequent drug-related toxicity in patients receiving DOC is peripheral neuropathy. The for candidate agents directed at common retroviral functions such as reverse transcription (Gardner & Luciw, 1989) . DDC in this animal model system has already been shown to increase survival (Brasham et a/., 1991) and to reduce the splenomegaly and Iymphoadenopathy (Rossi et el., 1993) that are typical signs of the disease. The results reported in this paper provide additional information about both drug efficacy and toxicity. As regards efficacy, we have shown that DDC reduces not only the LP-BM5 Iymphoadenopathy but also virus integration in the DNA of the lymph nodes of infected treated animals.
The main toxicities that appear to be associated with long-term DDC administration in mice involve several organs. Histological examinations have revealed hepatocellular vacuolation, megakariocyte depletion in the bone marrow and reduction of spleen hemopoiesis. Thrornbocytopenias has been observed in clinical trials with DDC (Yarchoan et a/., 1988) , and in vitro inhibition of a megakaryoblastic cell line has been described (Inoue et a/., 1989) . However, anaemia was not reported, and in vitro inhibition of erythroid colony-forming units (CFUe) was noted at drug concentrations much higher than those used in this study (Du et a/., 1990) . Thus, DDC appears to affect erythropoiesis more in mice than in humans. Hepatic toxicity has not been documented in humans, but appears in mice (this paper) and in cats (Polas et a/., 1990) . It should be noted that hepatocellular vacuolation 
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bases for in vivo DDC toxicity are not well known. /n vitro, DDC at therapeutic concentrations has been shown to cause a selective loss of mitochondrial DNA (Chen and Cheng, 1989) . In the few in vivo toxicity studies published (Lindstrom et a/., 1990; Polas et a/., 1990; Feldman et a/., 1992) , DDC appears to have other effects including megakariocyte hypoplasia and hepatocellular vacuolation. Furthermore, several reports (Balzarini et a/., 1988; Polas et a/., 1990 : Rossi et el., 1992 , including data obtained in our laboratory , have provided evidence for a cell-dependent toxicity.
In an attempt to understand better the in vivo mechanism(s) of toxicity associated with long-term DDC administration we have used the LP-BM5 murine immunodeficiency model. Murine AIDS shows many similarities to human AIDS, justifying the use of the LP-BM5 murine model, as already discussed by Jolicoeur (1991) and Morse et at. (1992) . This is probably not the ideal model in which to study AIDS, but it can provide some information that will be useful in defining early therapeutic intervention or prophylaxis offering a cost-effective screening system is not evident in the infected mice (Fig. 1) . Thus infection may also mask liver toxicity in humans. The results reported in this paper clearly show that DOC affects mitochondrial DNA content in vivo. The reduction by 22-25% of the mitochondria DNA in the lymph nodes of DOC-treated mice is not dramatic, as shown in in vitro studies on human cell lines (Chen and Cheng, 1989) . However, DOC phosphorylation is essential for this toxicity (Chen and Cheng, 1992 ) and mice cells are less able than human cells to phosphorylate DOC . This fact could also explain the almost normal blood lactate concentration found in our studies. Because of the difference in DOC metabolism mentioned above between human and murine cells and the limitations of animal models in predicting human toxicity the results reported in this paper should be extrapolated to humans with caution. Interestingly, DOC appears to restore almost completely the phytohemagglutinin (PHA) response of T cells which is normally reduced by about 50% in infected mice (Fig. 6) . In.contrast, no effect was found on the proliferative respons of B cells.
In conclusion, the results reported in this paper confirm that DOC reduces the typical signs of the disease but does not prevent the development of MAIDS. Similar conclusions were also drawn from studies in which much higher DOC concentrations were used (Brasham et el., 1991) . Like other nucleoside analogues, DOC appears to have a cell-specific toxicity profile, probably as a result of differences in DOC phosphorylation in the different cell types. Furthermore, these studies highlight the need for the development of specific drug-targeting systems. In fact, the delivery of drugs only to cells that are potentially infectable, such as lymphocytes and macrophages, would avoid most of the drug toxicities. The results already obtained in our laboratory suggest that such targeting is feasible , and the data reported here confirm that it is urgently needed.
Materials and Experimental Procedures: Virology
Virus and animals LP-BM5 virus was kindly provided by Robert Yetter (Veterans Administration Hospital, Baltimore, MD) and was maintained in a persistently infected SC-1 cell line as described in Mosier et at. (1987) . C57BU6 female mice (purchased from Nossan, Milan, Italy) were used at 4 weeks of age and were infected by a single intraperitoneal injection of 0.1 ml of the virus stock containing 6.6 x 10 5 cpm of reverse transcriptase.
Serum immunoglobulin determination
Serum IgG levels were determined using an ELISA technique. Briefly, polyvinylchloride microtitre plates (Sterlin, Hounslow, UK) were coated with serial dilutions of murine serum in 50 mM sodium borate, pH 8.5, and incubated for 48 h at 4°C. The DOC in murine immunodeficiency syndrome 159 plates were washed four times with 0.05% Tween 20 in phosphate-buffered saline (TPBS) and blocked with 1.2% BSA in TPBS for 30 min at room temperature. After two washings in TPBS, 100 pi of goat anti-mouse IgG horseradish peroxidase (HRP)-conjugate (Bio-Rad, Richmond, CAl, diluted 1:3000 in 0.2% BSA in TPBS, was added. After incubation for 3 h at room temperature, serum IgG was determined using a colour development solution containing 2.2 mM O-phenylenediamine. Absorbance was measured at 492 nm on Model 2550 EIA READER (Bio-Rad). Absolute serum IgG concentrations were obtained using known concentrations of standard mouse IgG.
Serum IgM levels were determined using the ICN immunodiffusion kit (ICN Biomedicals, Costa Mesa, CAl.
Identification of infected cells by immunocytochemistry
Bone marrow cells and splenocytes were stained with an anti-p30 antibody (Quality Biotech., Inc., Camden, NY) essentially as previously reported for macrophages and lymphocytes (Rossi eta/., 1993) .
Determination of mitochondrial DNA content
DNA was isolated from lymph nodes by lysis with 8 M urea, 0.3 M NaCI, 10 mM EDTA, 10 mM Tris HCI, pH 7.5, for 60 min at 37°C. Extraction was with phenol-chloroform-isoamyl alcohol (25:24:1) and then with chloroform-isoamyl alcohol (24:1). For Southern blot experiments total cellular DNA (5 pg) was digested with the restriction enzyme Bam HI, analysed on 0.8% agarose gel and transferred to the nylon membrane under the conditions recommended by the manufactures (Amersham, UK). To detect the mitochondrial DNA a 1544-bp mitochondrial DNA fragment labelled with 32p was used as a probe. The mitochondrial DNA probe (kindly provided by Dr Gadaleta, University of Bari, Italy) spans the region from nucleotide 2578 to 4122 in the complete human mitochondrial DNA. As a result of the high homology between human and mouse mitochondrial DNA (Bibb et a/., 1981) this probe recognizes human and mouse sequences equally well (data not shown). The relative reduction of mitochondrial DNA in animals receiving DDC compared to the untreated animals was found by laser scan densitometry of the autoradiograph with an LKB Ultroscan XL laser scan densitometer.
PCR analyses of LP-BM5 integration
The following oligonucleotide primers were used for the arnplification of integrated BM5d genome: a 5' primer, 5'-AACCnC-CTCCTCTGCCA-3' (sense), corresponding to nucleotides 1456-1473 in the viral sequence (Chattopadhyay et a/., 1991) , and a 3'-primer, 5'-ACCACCTCTCGGGCTTTC-3' (antisense), corresponding to nucleotides 1579-1596 of the BM5d genome. A second pair of oligonucleotide primers was used for the amplification of a p12 gag gene homologue present in the mouse genome and recently discovered in our laboratory (EMBL Data Library accession n X72930). This amplification served as an endogenous standard for the evaluation of relative BM5d integration in the mouse genome. The nucleotide primers for the amplification of the endogenous virus were a 5' primer, 5'-TGACCTTTACACTGCCCTTATC-3' (sense), and a 3' primer, 5'-CGTTTTCCTCCTCGGACTTATA-3' (antisense). PCR, performed in a Perkin-Elmer thermocycler, was performed in a final volume of 50 pi containing 1 pg of genomic DNA, 50 mM KCI, 10 mM Tris HCI, pH 8.3, 1 mM MgCI 2, 0.005% Tween 20, 0.005% NP-40, 0.001 % gelatin, 200 pM each of the four deoxyribonucleoside triphosphates, 20 pmol of each primer and 2.5 U of Replitherm DNA polymerase (Epicentre, UK). The reaction mixtures were subjected to 28 cycles of denaturation at 90 DC for 30 s, annealling at 57 DC for 7 s, and extension at 72 DC for 30 s followed by final extension at 72 DC for 10 min. The PCR products were analysed by electrophoresis on 2% agarose gel, transferred onto nylon membrane and hybridized with 32P-labelled D30 probe [probe D30 derived from the 137-bp Smal-Xhol gag fragment of BM5d (Aziz et al., 1989) kindly provided by P. Jolicoeur, Montreal, Canada]. Labelling of the DNA probe was performed using the random primer DNA-labelling kit from Bio-Rad (CA).
Other determinations
Flow cytometry analysis of lymphocytes and blood lactate determinations were performed as in Rossi et al. (1993) . DDC concentration in plasma was determined by HPLC analysis as in Brandi et al. (1991) .
[3H]-Thymidine incorporation upon lymphocyte stimulation was performed as previously described . DDCtherapy DDC (Fluka) was administered orally in the drinking water at a concentration of O-,lmg mr' for 3 months. In infected animals, DDC treatment began with viral inoculation. This treatment regime. was previously (Rossi et el., 1993) . found to result in a mean plasma drug concentration of 0.2 ± 0.02 pM (mean ±SD of four determinations on pooled blood samples from groups of four animals of which two were bled in the morning and two in the afternoon).
Histopathological examinations
Samples of spleen, bone marrow and liver from three animals in each treatment group were fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS), embedded in paraffin, sectioned, and stained with hematoxylln-sosln (spleen and liver) or May-Grunwald Giemsa stain (bone marrow).
